A Study On MicroRNA As The Diagnostic Biomarker Of Breast Cancer

Background:Breast cancer was one of the most common type of cancer and the leading cause of cancer-related death in women. The success of curing the breast cancer depended largely on the staging of the neoplasm during diagnosis. So the early diagnosis of breast disease is the effective measure in improving the prognosis. At present, there is no non-invasive biomarker that has both good sensitivity and specificity in breast cancer diagnosis. MicroRNA, is a class of about 22bp small molecule single-stranded nucleotide RNA. Due to its stability in the peripheral blood, it is increasingly becoming a novel biomarker. The aim of this study is to find circulating biomarkers in early diagnosis of breast cancer.Method:The object of study was cell-free microRNA in serum samples. High-throughput screening Chip expression analysis and accurate verification method (Taqman probe real-time fluorescent quantitative PCR technology) were applied in the research. The research focused on obvious changing serum microRNA spectrum compared before and after surgery. Combined with clinical material, we tried to explore the value of microRNA spectrum which was closely related to tumor in the area of early diagnosis in both training set and ventilation set. Sensitivity, specificity, and ROC curves were used to assess its diagnostic value.Result:After applying the High-throughput screening chip, statistical analysis and real-time quantitative PCR in the training set and validation set, we found that the expression of serum miR-130b-5p, miR-151a-5p, miR-206, and miR-222-3p had a significant difference in breast cancer patients and the control group. All of these had the potential value of breast cancer diagnosis. Specificity, sensitivity and receiver operating curves plotted were derived in this analysis. (miR-130b-5p:training set, AUC = 0.7486, sensitivity of 60.87%, specificity of 86.96%; validation set, AUC= 0.7276, sensitivity 73.21%, specificity 72.09%. miR-151a-5p:training set, AUC=0.7599, sensitivity of 61.90%, specificity of 79.17%; validation set, AUC= 0.7959, sensitivity 76.79%, specificity 75.00%. miR-206:a training set, AUC= 0.7302, sensitivity of 52.38%. specificity 87.50%; validation set, AUC= 0.8605, sensitivity 72.55%, specificity 86.05%. miR-222-3p: training set, AUC= 0.7066, sensitivity of 66.67%, specificity of 70.83%; validation set, AUC= 0.8860, sensitivity of 85.71%, specificity of 79.55%). The united four microRNA had better diagnostic value and had a relatively better sensitivity and specificity (united four microRNA, training set:AUC= 0.8457, sensitivity of 85.00%, specificity of 65.22%; validation set:AUC= 0.9309, sensitivity of 84.31%, specificity of 83.33%).Conclusion:serum miR-130b-5p, miR-151a-5p, miR-206 and miR-222-3p were potential biomarkers for breast cancer diagnosis.